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Abstract
Introduction Tofacitinib is an oral Janus kinase inhibitor
for the treatment of rheumatoid arthritis (RA), and is being
investigated for the treatment of psoriasis. Both conditions
can present in women of child-bearing potential, but
pregnancy was an exclusion and discontinuation criterion
in tofacitinib randomized controlled trials (RCTs) because
of the unknown effects of tofacitinib on mother and child.
Tofacitinib is a small molecule that has the potential to
cross the placenta.
Objective The objective was to report outcomes of preg-
nancy cases identified through April 2014 from tofacitinib
RA/psoriasis RCTs, RA post-approval non-interventional
studies, and spontaneous adverse-event reporting.
Methods Pregnancy outcomes were categorized as fol-
lows: healthy newborn, medical termination, fetal death,
congenital malformation, spontaneous abortion, or pend-
ing/lost to follow-up.
Results Out of 9815 patients, 1821 female patients of
child-bearing age were enrolled in the RA/psoriasis RCTs;
47 women became pregnant, including 33 who received
tofacitinib monotherapy, 13 who received combination
therapy with methotrexate (RA patients only), and one
patient whose therapy was still blinded. No fetal deaths
were reported. One congenital pulmonary valve stenosis
(monotherapy, n = 1), seven spontaneous abortions
(monotherapy, n = 4; combination therapy, n = 3), and
eight medical terminations (monotherapy, n = 4; combi-
nation therapy, n = 3; blinded therapy, n = 1) were
identified. Remaining cases reported healthy newborns
(n = 25) or were pending/lost to follow-up (n = 6). Forty-
four cases of paternal exposure to tofacitinib were reported
(monotherapy, n = 43; combination therapy, n = 1),
including five spontaneous abortions (monotherapy, n = 4;
combination therapy, n = 1), 23 healthy newborns, and 16
pending/lost to follow-up.
Conclusions The pregnancy outcomes reported in this
small number of RA/psoriasis patients appear similar to
those observed in the general population and in patients
treated with biologic therapies for inflammatory diseases.
However, definitive conclusions cannot be drawn, and
pregnancy outcomes in patients receiving tofacitinib will
continue to be monitored.
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Key Points
Tofacitinib is an oral Janus kinase inhibitor for the
treatment of rheumatoid arthritis (RA), and is being
investigated for the treatment of psoriasis.
There are currently no adequate or well-controlled
studies of tofacitinib or any disease-modifying
antirheumatic drug in pregnant women.
Pregnancy outcomes reported in the tofacitinib RA
and psoriasis safety databases appear similar to those
observed in the general population and in patients
treated with biologic therapies for inflammatory
diseases.
1 Introduction
Tofacitinib is an oral Janus kinase (JAK) inhibitor for the
treatment of rheumatoid arthritis (RA) [1–7]; it is also being
investigated for the treatment of psoriasis [8–10]. Clinical
programs have studied tofacitinib dosed at 1–30 mg twice
daily (BID) and 20 mg once daily (QD) for RA, and
5–50 mg BID and 60 mg QD for psoriasis, and dosages of 5
and 10 mg BID have been brought forward to phase 3
studies for both RA and psoriasis. Tofacitinib 5 mg BID
was approved by the US Food and Drug Administration
(FDA) in 2012 for the treatment of moderately to severely
active RA and has since been approved in many other
countries [11]. More recently, this year, tofacitinib 11 mg
QD (extended-release tablet) was also approved by the FDA
for the treatment of moderately to severely active RA.
Pre-clinical animal studies have shown that tofacitinib
was teratogenic in rats and rabbits when given at exposures
146 times and 13 times greater than the human dosage of
5 mg BID [11]. Teratogenic effects included membranous
ventricular septal defects and skeletal/cranial malforma-
tions or variations. There was an observed increase in post-
implantation loss (56.8 % in rats dosed at 100 mg/kg vs.
4.0 % in the control group) and a decrease in the number of
viable fetuses and mean fetal body weight.
Although RA and psoriasis are conditions that may be
present in women of child-bearing potential, there are
currently few adequate or well-controlled studies of dis-
ease-modifying antirheumatic drugs (DMARDs), and none
of tofacitinib, in pregnant women [12]. Tofacitinib is a
small molecule that could potentially cross the placenta,
and because of the unknown risks of tofacitinib to mother
and child, randomized controlled trial (RCT) protocols
excluded pregnant patients and required the use of highly
effective contraception by women of child-bearing poten-
tial. Furthermore, study medication was required to be
discontinued in any patients who became pregnant. Nev-
ertheless, pregnancies did occur and outcomes were
recorded and followed up, where possible. Additionally,
some clinical trials involved the use of methotrexate
(MTX), a known teratogen associated with a range of
embryopathies [13].
The aim of this analysis was to describe reported preg-
nancies and their outcomes from tofacitinib RA and pso-
riasis clinical safety databases up to April 2014. In
addition, RA post-approval non-interventional studies and
spontaneous adverse-event (AE) reporting were also
analyzed.
2 Methods
Cases of pregnancy were identified from a search of AEs in
Pfizer’s safety databases through April 30, 2014, including
the tofacitinib clinical development programs in RA and
psoriasis, post-approval non-interventional studies, and
spontaneous AE reporting from all countries around the
world where tofacitinib is marketed. Pregnancy cases from
post-marketing non-interventional studies in the USA and
Canada were reported via the Organization of Teratology
Information Specialists (OTIS) registry, a not-for-profit
organization monitoring medications, chemicals, and other
exposures during pregnancy [14].
Patients enrolled in the RA and psoriasis RCTs had to be
aged at least 18 years at the time of informed consent (see
Electronic Supplementary Material 1 for a list of studies
from the RA and psoriasis clinical development programs).
If consent to follow pregnancy to outcome was provided by
the patient (or patient’s partner), then sites were responsi-
ble for gathering information on pregnancy outcomes
through normal AE reporting on pregnancy follow-up
forms. In addition, clinical sites were requested to provide
additional information based on projected outcome date. In
the absence of follow-up information, a case would not be
updated with outcome and would be recorded as ‘lost to
follow-up’. Pregnancy cases reported in this analysis of
RCTs included females who received study medication at
the time of conception and/or during the course of preg-
nancy. In addition, cases of identified paternal exposure to
tofacitinib were included in this study. All cases were
reviewed for any pregnancy-related outcomes and catego-
rized as either healthy newborn (including preterm births
and newborns with low birth weight), medical termination,
fetal death (defined as death after 20 weeks’ gestation),
congenital malformation, spontaneous abortion, or pend-
ing/lost to follow-up (including refusal of consent to fol-
low-up).
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3 Results
3.1 Pregnancy Cases
Of the 9815 RA and psoriasis patients enrolled in the Pfi-
zer-sponsored tofacitinib RCTs, 47 women became preg-
nant (Table 1).
A total of 6192 patients with 16,839 patient-years of
tofacitinib exposure were enrolled in RA RCTs, from
whom 31 cases of pregnancy (2.4 %) were identified in
1309 female patients aged 18–44 years (Table 1). Tofaci-
tinib exposure occurred within the first trimester in all but
two cases, where exposure occurred in the second and third
trimester, respectively.
A total of 3623 patients with 5204 patient-years of
tofacitinib exposure were enrolled in psoriasis RCTs, from
whom 16 cases of pregnancy (3.1 %) were identified
among 512 female patients aged 18–44 years (Table 1).
Tofacitinib exposure occurred during the first trimester for
all cases (Table 1).
3.2 Pregnancy Outcomes in RA Patients
A total of 31 cases were reported in the RA RCTs: 18 cases
(58.1 %) in patients receiving tofacitinib monotherapy, and
13 cases (41.9 %) in those treated with tofacitinib and
MTX (Fig. 1a; Table 2). One pregnancy resulting in a
spontaneous abortion was identified in a 34-year-old
female receiving placebo in combination with MTX
20 mg.
3.2.1 RA Patients on Tofacitinib Monotherapy
Among the 18 pregnancy cases identified in RA patients
who received tofacitinib monotherapy, one congenital
malformation (pulmonary valve stenosis; 5.6 %) was
identified in a 32-year-old patient with hypertension
treated with the angiotensin II receptor antagonist
losartan (50 mg QD), who received tofacitinib 5 mg
BID. Estimated duration of in utero tofacitinib exposure
was 35 days, gestational age at delivery was 38 weeks,
Table 1 Patient characteristics for women who received tofacitinib and became pregnant in the RA and psoriasis clinical trials
Characteristic RA Psoriasis
Patients with reports of pregnancy (n/N of female patients aged 18–44a) 31/1309 (2.4 %) 16/512 (3.1 %)
Median age (range), yearsb 31 (22–40) 27 (19–40)
Study medication (n; % of identified cases) Tofacitinib monotherapy (18;
58.1 %)
Tofacitinib ? MTX (13;
41.9 %)
Tofacitinib monotherapy (16;
100 %)
Pregnancy outcomes, n (% of identified cases)
Fetal death 0 (0.0 %) 0 (0.0 %)
Congenital malformation 1 (3.2 %) 0 (0.0 %)
Spontaneous abortion 6 (19.4 %) 1 (6.3 %)
Healthy newborn 16 (51.6 %) 9 (56.3 %)
Medical termination 4 (12.9 %) 4 (25.0 %)
Lost/pending to follow-up 4 (12.9 %) 2 (12.5 %)
Range of total time on study medication at time of pregnancy identification,
range, daysc
28–1344 21–349
Duration of in utero study medication exposure, daysd
Range 7–244 14–43
B90 days 29 cases 16 cases
[90 and B180 days 1 case 0 case
[180 days 1 case 0 case
MTX methotrexate, RA rheumatoid arthritis
a Enrolled in RA or psoriasis clinical trials
b Based on 30 and 15 patients with data, respectively
c Data available for n = 26 and n = 10 patients in the RA and psoriasis clinical trials, respectively
d Based on when pregnancy occurred and when the subject was discontinued from the study drug
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and no delivery complications or fetal distress were
reported. Infant birth weight was 3.2 kg, length 48 cm,
and the Apgar score was 8 at 1 min and 9 at 5 min post-
delivery.
Three spontaneous abortions (16.7 %) (5 mg BID,
n = 1; 10 mg BID, n = 1; 15 mg BID, n = 1) and one
medical termination (5.6 %) (10 mg BID) were reported.
Eleven patients (61.1 %) gave birth to healthy newborns
(5 mg BID, n = 6; 10 mg BID, n = 5); among the five
healthy newborns reported in patients receiving tofacitinib
10 mg BID, one low-birth-weight infant (2.1 kg) was
delivered at 37 weeks (10th percentile at
37 weeks = 2.5 kg [15]), and one infant was delivered
preterm (35 weeks’ estimated gestational age; 2.4 kg; 10th
percentile at 35 weeks = 2.2 kg [15]).
3.2.2 RA Patients on Tofacitinib/MTX Combination
Therapy
Among the 13 pregnancies identified in patients who
received tofacitinib in combination with MTX, three
spontaneous abortions (23.1 %) occurred, all in patients
receiving tofacitinib 10 mg BID (MTX 20 mg, n = 1;
MTX unspecified dose, n = 2). Three medical terminations
(23.1 %) were reported: two in patients dosed with tofac-
itinib 5 mg BID (MTX 20 mg, n = 1; MTX unspecified
dose, n = 1) and one in a patient who received tofacitinib
10 mg BID and an unspecified dose of MTX. Five patients
(38.5 %) gave birth to healthy newborns, of whom one was
treated with 5 mg QD (MTX 2.5 mg), two were treated
with 5 mg BID (MTX 17.5 mg, n = 1; MTX unspecified
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dose, n = 1), one was treated with tofacitinib 10 mg BID
(MTX unspecified dose), and one was treated with tofaci-
tinib 20 mg QD (MTX 25 mg). Two patients who received
tofacitinib in combination with MTX were pending/lost to
follow-up (tofacitinib 5 mg BID/MTX 2.5 mg, n = 1;
tofacitinib 10 mg BID/MTX unspecified dose, n = 1).
3.3 Pregnancy Outcomes in Psoriasis Patients
Sixteen pregnancies were reported among patients in the
psoriasis RCTs; each patient received tofacitinib as
monotherapy (Table 2). One spontaneous abortion
(6.3 %) was reported (tofacitinib 10 mg BID) and four
medical terminations (25.0 %) were reported (tofacitinib
5 mg BID, n = 1; tofacitinib 10 mg BID, n = 2; blinded
therapy, n = 1) (Fig. 1b; Table 2). Nine women
(56.3 %) gave birth to healthy newborns (5 mg BID,
n = 1; 10 mg BID, n = 8). No fetal deaths or congenital
malformations were identified. Two outcomes (12.5 %)
of patients receiving tofacitinib 10 mg BID were pend-
ing/lost to follow-up.
Table 2 Pregnancy outcomes by tofacitinib dose after maternal exposure
Median age
(range), years
Fetal
deatha
Congenital
malformation
Spontaneous
abortion
Other outcomes
Healthy
newborn
Medical
termination
Pending/lost to
follow-up
RA clinical trials: tofacitinib
monotherapy all doses (n = 18)
31 (22–39) 0 1 3 11b 1 2
Tofacitinib monotherapy 5 mg BID
(n = 8)
27 (22–39) 0 1 1 6 0 0
Tofacitinib monotherapy 10 mg BID
(n = 9)
32 (27–39) 0 0 1 5b 1 2
Tofacitinib monotherapy 15 mg BID
(n = 1)
31 0 0 1 0 0 0
RA clinical trials: tofacitinib all
doses ? MTX all doses (n = 13)
32 (22–40)d 0 0 3 5 3 2
Tofacitinib 5 mg QD ? MTX 2.5 mg
(n = 1)
34 0 0 0 1 0 0
Tofacitinib 5 mg BID ? MTX
10 mg (n = 1)
22 0 0 0 0 0 1
Tofacitinib 5 mg BID ? MTX
17.5 mg (n = 1)
29 0 0 0 1 0 0
Tofacitinib 5 mg BID ? MTX
20 mg (n = 1)
24 0 0 0 0 1 0
Tofacitinib 5 mg BID ? MTX
unspecified dose (n = 2)
34 (31–36) 0 0 0 1 1 0
Tofacitinib 10 mg BID ? MTX
20 mg (n = 1)
28 0 0 1 0 0 0
Tofacitinib 10 mg BID ? MTX
unspecified dose (n = 5)
36 (32–40)d 0 0 2 1 1 1
Tofacitinib 20 mg QD ? MTX 25 mg
(n = 1)
25 0 0 0 1 0 0
Psoriasis clinical trials: tofacitinib
monotherapy all doses (n = 16)
27 (19–40)d 0 0 1 9 4 2
Tofacitinib monotherapy 5 mg BID
(n = 2)
34 (31–36) 0 0 0 1 1 0
Tofacitinib monotherapy 10 mg BID
(n = 13)
27 (19–40)d 0 0 1 8 2 2
Blinded therapyc (n = 1) 26 0 0 0 0 1 0
BID twice daily, MTX methotrexate, QD once daily, RA rheumatoid arthritis
a Death after 20 weeks’ gestation
b Includes two preterm/low-birth-weight newborns
c Study still ongoing and blinded
d Includes one patient for whom age was not known
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3.4 Pregnancy Outcomes Identified in Non-
interventional Safety Studies and Spontaneous
AE Reporting (up to April 2014)
In addition to the cases identified in the tofacitinib RCTs
(described in Fig. 1; Tables 1 and 2, and above), one
spontaneous report was received (pending/lost to follow-up
case in a patient receiving tofacitinib monotherapy) and
two pregnancies were reported in non-interventional stud-
ies: one spontaneous abortion, which occurred in a 33-year-
old patient treated with tofacitinib in combination with
MTX (10 mg), and one pending/lost to follow-up case,
which occurred in a patient receiving tofacitinib
monotherapy.
3.5 Overview of Paternal Exposure in RA
and Psoriasis Clinical Trials
Forty-four cases of paternal exposure to tofacitinib were
identified in RA (n = 3; age 35–42 years) and psoriasis
(n = 41; age 22–54 years) RCTs. In the 39 cases where
sufficient details were provided, exposure occurred around
the time of conception and within the first trimester. Two
(66.7 %) of the RA cases were healthy newborns; the other
resulted in a spontaneous abortion in a patient who
received tofacitinib 10 mg BID and MTX 7.5 mg. In
addition, two healthy newborns were identified in tofaci-
tinib RA clinical trials, in patients who did not receive
tofacitinib: one in a patient who received placebo and
MTX, and one in a patient who received adalimumab.
Of the 41 cases reported in patients with psoriasis, 21
(51.2 %) were healthy newborns, four (9.8 %) were
spontaneous abortions, and 16 (39.0 %) were pending/lost
to follow-up.
4 Discussion
This study reports pregnancies from a large database of
patients in the tofacitinib clinical development program
(n = 9815). Forty-seven cases (31 and 16 cases in RA and
psoriasis patients, respectively) were reported after mater-
nal exposure; there were 25 healthy newborns, no reports
of fetal death, seven spontaneous abortions, eight medical
terminations, one congenital malformation (pulmonary
valve stenosis), and six cases pending/lost to follow-up.
Paternal exposure to tofacitinib was also reported in 44
pregnancies fathered by men in the RA and psoriasis RCTs,
resulting in 23 healthy newborns, five spontaneous abor-
tions, and 16 cases pending/lost to follow-up. One spon-
taneous abortion and two pending/lost to follow-up cases
were reported in the non-interventional safety studies and
through spontaneous AE reporting (up to April 2014).
The observed frequencies of congenital malformations
(2 %) and spontaneous abortions (15 %) across the RA and
psoriasis RCTs are consistent with background risks in the
general population and in patients with RA or psoriasis. In
the general population of the USA, the background risk for
major birth defects is about 3 %, and for spontaneous
abortions is 15–20 % [16, 17]. Similar, or slightly lower,
background risks for spontaneous abortion have been
reported in other regions (UK *20 % [18], Denmark
13.5 % [19], China 7.9 % [20], and Brazil 14.0 % [21]). In
RA patients, studies have reported a background risk of
4.3 % for major congenital malformations and birth defects
[22], with an increased risk for pregnancy complications
dependent on RA activity [23–25]. In patients with mod-
erate to severe psoriasis, an increased risk for spontaneous
and induced abortions, macrosomic newborns, and pre-
mature rupture of membranes was reported [26, 27].
In the current analysis of RA RCTs, 13 of 31 reported
pregnancies occurred in patients receiving concomitant
MTX treatment, a known teratogen and abortofacient
[13, 28]. The current US prescribing information specifies
that MTX is contraindicated during pregnancy. Further-
more, a clear dose threshold has been reported for terato-
genic effects of MTX, with increased risk of abnormalities
during the first trimester with all doses but particularly with
dosages greater than 10 mg per week [13, 28–30]. In the 13
pregnancy cases reported herein, the dose of MTX received
ranged from 2.5 to 25 mg (where specified). Published
estimates from a cohort with rheumatic diseases indicated
pregnancy losses of 22.5 % in patients who did not receive
MTX versus 42.5 % for those receiving MTX [28]. These
observations suggest that MTX is likely to be a con-
founding factor in adverse pregnancy outcomes reported in
the tofacitinib RA RCTs; however, our data are currently
too limited to support MTX as the sole cause of the adverse
pregnancy outcomes reported in patients on combination
therapy.
Studies of biologic therapies have reported similar
pregnancy outcomes after maternal exposure to those
observed in this study [31–37]. Published data indicate an
association between risk of preterm delivery and increased
disease activity [23]. Here, two preterm births were
reported for tofacitinib among the 16 RA healthy newborns
and no cases were identified in the psoriasis RCTs.
Tofacitinib is a small molecule (free-base form 312.4
Daltons) that has the potential to cross the placenta. Pre-
clinical animal studies have demonstrated that treatment
with tofacitinib led to a reduced number of viable fetuses
and a reduced fetal body weight in rats [11]. In addition,
tofacitinib was shown to be secreted in the milk of lactating
rats [11]. As the tofacitinib clinical development program
was designed to limit any risks to pregnant mother and
child, there are currently no adequate and well-controlled
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studies in pregnant or nursing women. The current US
prescribing information for tofacitinib specifies that tofac-
itinib should be used during pregnancy only if the potential
benefit justifies the potential risk to the fetus [11].
There are limitations to the currently reported data.
Although results were drawn from relatively large clinical
trial databases, this was not a prospective analysis and a
relatively small number of pregnancies were identified.
Additionally, outcomes were not available for six (12.8 %)
of the reported pregnancies after maternal exposure, and
limited information is available on the exact date of con-
ception and gestational age in several cases. Finally, clear-
cut associations between the effects of tofacitinib on
pregnancy outcomes cannot be drawn because of con-
founders, such as underlying RA and psoriasis disease
activity, concomitant treatments, and other concurrent
medical conditions.
5 Conclusion
Based on these limited clinical data, unintentional exposure
to tofacitinib during conception/pregnancy does not appear
to be associated with an increased risk to the fetus when
compared with risks identified in the general population
and specifically reported in RA and psoriasis patients.
However, definitive conclusions cannot be drawn and
pregnancy outcomes in patients receiving tofacitinib will
continue to be monitored in RCTs, through routine phar-
macovigilance, and via a post-approval safety study with
the OTIS registry. As pregnancy was an exclusion criterion
in the tofacitinib clinical development program, it is
expected that pregnancy outcomes may occur more fre-
quently in the post-approval setting. If exposure to tofaci-
tinib occurs as a result of unintended pregnancy, a benefit–
risk discussion should be undertaken between the patient,
family, and appropriate healthcare professionals.
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